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Structured Abstract  28 
Purpose of review: Food allergy has become more prevalent in recent decades. Without a 29 
curative treatment for food allergy, prevention is key. Can we intervene and halt the food 30 
allergy epidemic? 31 
Recent findings: There are three main hypotheses to explain the rise in food allergy: the dual-32 
allergen exposure hypothesis, the hygiene hypothesis and the vitamin D hypothesis. In a recent 33 
systematic review of randomized controlled trials, only introduction of allergenic foods, 34 
namely egg and peanut, in the diet at the time of weaning and avoidance of temporary 35 
supplementation with cow’s milk formula in the first few days of life showed low to moderate 36 
evidence of a preventative effect.  37 
Summary: For primary prevention, introduction of allergenic foods at the time of weaning and 38 
avoidance of temporary supplementation with cow’s milk formula in the first few days of life 39 
has been recommended. Introduction of foods once allergy has been excluded may be 40 
beneficial for sensitized subjects (secondary prevention). Once food allergy has been 41 
established, it is important to minimise complications (tertiary prevention) through allergen 42 
avoidance, timely treatment of allergic reactions, control of atopic co-morbidities and dietetic 43 
and psychological support, as appropriate. Immunomodulatory treatments can potentially be 44 
disease-modifying and require further research. 45 
 46 
Abstract word count: 199 47 
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Introduction 50 
Food allergy affects about 8% of children in Western countries (1, 2) and its prevalence is 51 
increasing in the adult age group (3), probably reflecting both an increase in incidence and in 52 
life-time prevalence as children grow older. Food allergy has also been rising in other parts of 53 
the world, like South East Asia and Africa, particularly in urban centres (4, 5). Hospital 54 
admissions for food allergy and severity of food allergy have also increased, with a recent US 55 
study showing that about 40% of food allergic children have multiple food allergies, severe 56 
food allergies and have been prescribed an adrenaline auto-injector (1). Although many food 57 
allergies resolve spontaneously, others can be life-long. The 4-year follow-up of the Healthnuts 58 
cohort from Melbourne in Australia showed that the prevalence of food allergy decreased from 59 
11% at 1 year to 3.8% at 4 years of age (6). The Schoolnuts study, in the same geographical 60 
area, showed a prevalence of food allergy of 4.5% at 10-14 years of age (7). The natural history 61 
of food allergy seems to be changing over time with more recent studies reporting a later 62 
acquisition of tolerance than previously, although such reports can be influenced by the 63 
population studied, the type of food allergy (e.g. whether IgE or non-IgE-mediated) and the 64 
approach adopted to assess resolution. Over the past few decades, we have witnessed an 65 
increase in the prevalence, severity and persistence of food allergy overall.  66 
 67 
Why is the world becoming more allergic to food? 68 
There are 3 main working hypotheses to explain the food allergy epidemic (Figure 1): 69 
- Dual allergen exposure hypothesis 70 
- Hygiene hypothesis 71 




Dual allergen exposure hypothesis 75 
Atopic eczema is probably the main risk factor for food allergy, particularly early onset 76 
moderate-severe eczema (8, 9). The dual allergen exposure hypothesis, proposed by Gideon 77 
Lack in 1996, postulates that the development of food allergy results from the combination of 78 
time, route and dose of exposure to food allergens in early life (10). The balance between 79 
exposure through the gastro-intestinal tract, which is tolerogenic, particularly in high doses, 80 
and exposure through the skin, particularly to low doses of allergen through abraded inflamed 81 
skin affected with eczema, determines food allergy risk. When exposure via the gastrointestinal 82 
tract happens before exposure through the skin, tolerance is established; conversely, when 83 
exposure via the skin happens before the food is introduced in the diet, food allergy can 84 
develop. The dual allergen exposure hypothesis was tested in the Learning Early About Peanut 85 
Allergy (LEAP) randomized controlled trial (RCT), which demonstrated that early peanut 86 
consumption, from age 4-11 months, prevented the development of peanut allergy by the age 87 
of 5 years with 81% relative reduction in the prevalence of peanut allergy (11). This effect was 88 
sustained after 1 year of peanut avoidance, suggesting that the preventative effects were long-89 
lasting (12). The higher prevalence of peanut allergy in the avoidance arm was evident 90 
immunologically with peanut avoiders having larger wheals on skin prick testing to peanut, 91 
higher prevalence of high peanut and Ara h 2-specific IgE levels and higher proportion of 92 
activated basophils, with basophil activation being inversely correlated with ratios of IgG4/IgE 93 
to peanut (11-13).  94 
 95 
Hygiene hypothesis 96 
The hygiene hypothesis was proposed by David Strachan in the 1989 following the observation 97 
that children from larger families had less asthma and allergic rhinitis. For food allergies, 98 
number of siblings and dog ownership have been identified as protective factors, probably 99 
 5 
related to greater microbial exposure (14, 15). The gut microbiome has been implicated in the 100 
development of food allergy and available evidence has recently been reviewed (16). With oral 101 
tolerance developing in the gut, commensal microbiota can modulate immune development 102 
and are required for a healthy immune response to foods (17). Observational studies in humans 103 
have showed different microbiota between food allergic and non-allergic individuals and 104 
between food allergic children who resolve their food allergies and children with persistent 105 
food allergies (18-21). Studies in mouse models have demonstrated that intestinal microbiota 106 
can transfer susceptibility or resistance to the development of food allergy, supporting its 107 
implication in this condition, and have shed light on the mechanisms of their effects (17, 22). 108 
Such mechanistic studies have allowed to understand the modifications to the immune system 109 
induced by the microbiota and to identify key regulatory cells induced in the GALT as a 110 
consequence of the introduction of solid foods in the diet, confirming that both the microbiota 111 
and allergen exposure are required for the establishment of oral tolerance to foods.  112 
 113 
Vitamin D hypothesis 114 
Observational studies have documented a greater prevalence of reported food allergies, of 115 
emergency visits for food allergic reactions and of prescriptions of adrenaline auto-injectors in 116 
geographical areas with lower sun exposure (23). In the Healthnuts study, vitamin D 117 
insufficiency was more common in infants with food allergy, with or without eczema, 118 
compared to infants with eczema only and to infants with neither eczema nor food allergy (24). 119 
Vitamin D insufficiency was also more common in children with multiple food allergies 120 
compared to children with a single food allergy (24). However, vitamin D levels can be 121 
influenced by various factors, including vitamin D binding protein levels and genetic 122 
polymorphisms influencing vitamin D metabolism, which can explain the conflict with results 123 
of other studies (25). A recent systematic review of the literature failed to find evidence to 124 
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support vitamin D supplementation in pregnancy (1 RCT and 1 observational study), lactation 125 
(0 studies), infancy (1 observational study) and childhood (0 studies) for primary food allergy 126 
prevention (26). Further studies are needed, possibly with patient stratification according to 127 
genotype and taking into account other factors affecting vitamin D levels (23).  128 
 129 
Can we stop the food allergy epidemic? 130 
With the alarming increase in prevalence, severity and persistence of food allergy and in the 131 
absence of a curative treatment, the hope of changing the current burden of food allergy is on 132 
prevention. There are three levels of prevention to consider:  133 
- Primary prevention, i.e. reducing food allergy before allergic sensitisation develops; 134 
- Secondary prevention, i.e. reducing food allergy after allergic sensitisation but before 135 
clinical food allergy develops; 136 
- Tertiary prevention, i.e. minimising the consequences of clinical food allergy.  137 
 138 
Primary prevention  139 
Recently, a task force of the European Academy of Allergy and Clinical Immunology (EAACI) 140 
published a systematic review of RCT covering various interventions that could possibly 141 
modify the food allergy risk in the first year of life (27), namely food allergen ingestion during 142 
pregnancy or lactation, breastfeeding, milk formulas (standard cow’s milk formula, hydrolysed 143 
formulas, soy-based formulas), introduction of complementary foods, vitamin 144 
supplementation, ingestion of fish oil, prebiotics, probiotics and synbiotics, application of 145 
emmolients, prophylactic allergen immunotherapy and BCG vaccination. From the available 146 
evidence, the only interventions that showed an effect with low to moderate certainty were the 147 
ones related to the introduction of allergenic foods in the diet. Introducing cooked egg and 148 
peanut in the diet at weaning (cooked egg from 6 months and peanut from median 7.8 months) 149 
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led to an absolute reduction in the prevalence of egg (29%) and peanut (12-23%) allergies with 150 
a moderate certainty of effect (28). Avoiding temporary supplementation with standard cow’s 151 
milk formula in the first week of life was estimated to reduce in 6% the prevalence of cow’s 152 
milk allergy with low certainty of effect (28).  153 
Based on this systematic review, the EAACI will be soon publishing the guidelines for the 154 
prevention of food allergy. Recommendations (Table 1) include: 155 
- No avoidance of food allergens during pregnancy or breastfeeding;  156 
- Avoidance of temporary supplementation with cow’s milk formula in the first week of 157 
life; 158 
- Introduction of well-cooked egg in the infant’s diet during weaning; 159 
- Introduction of peanut in the infant’s diet during weaning in populations with a high 160 
prevalence of peanut allergy. 161 
No recommendations could be made about vitamin or fish oil supplementation, the use of 162 
prebiotics, probiotics or synbiotics, emmolients, prophylactic use of allergen-specific 163 
immunotherapy or BCG vaccination with the view of preventing the development of food 164 
allergy. Other systematic reviews support these recommendations (29, 30). Various studies are 165 
ongoing to try to gather high-quality evidence on the effect of interventions on food allergy 166 
risk, including RCT of high-allergen diet in the second half of pregnancy and first 4 months of 167 
lactation (e.g. peanut and egg in PrEggNut RCT), perinatal administration of probiotics 168 
(NCT00200954), ceramide-based emollient (e.g. PEBBLES RCT, NCT03667651), proactive 169 
treatment of atopic eczema (e.g. SEAL RCT), introduction of cashew and other tree nuts in the 170 
infants’ diet (e.g. Cashew RCT, TreEat RCT), vitamin D supplementation (e.g. Vitality RCT, 171 
NCT02112734), whole cell pertussis vaccine instead of acellular pertussis vaccine (e.g. 172 
Optimum RCT) and BCG vaccination compared to placebo (e.g. MIS BAIR RCT).  173 
 174 
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Secondary prevention  175 
What can be done to prevent food allergy in infants and children who are already sensitized? 176 
Considering the current recommendations in, for instance, Europe (27), USA (31) and 177 
Australia (32) (Table 1), the main intervention to prevent food allergy in sensitized infants and 178 
children is the introduction of allergenic foods in the diet, in the case that they are not allergic 179 
to them. In the LEAP study (11), the preventative effect of early peanut consumption was 180 
indeed observed in the SPT-positive stratum, although with a lower relative risk reduction 181 
compared to the SPT-negative stratum (70% versus 86%, respectively). However, data is 182 
absent for infants with SPT of 5 mm or greater as they were excluded from the LEAP study at 183 
screening, as they were likely to already have developed peanut allergy (33).  184 
Most guidelines do not recommend allergy testing prior to introduction of the food, due to the 185 
eventual need for supervised challenges and the fact that limited resources could cause a delay 186 
in the food introduction, which could be counterproductive due to rapid immune changes in 187 
the first few months of life and consequent risk of developing food allergy (34, 35). However, 188 
the US guidelines recommend testing of high-risk infants prior to peanut introduction and also 189 
underscore the importance of being particularly proactive in this subgroup of infants, 190 
recommending peanut consumption from 4-6 months of age, whereas for the low risk group 191 
the introduction of peanut could be left to after 6 months, depending on the importance of 192 
peanut in the family’s diet (31).  193 
From the Allergist’s perspective, for the family’s that seek our advice prior to food 194 
introduction, it is justified to test for the foods that are commonly involved in food allergy in 195 
children and that the infant or child as yet to be exposed to via the oral route. This is particularly 196 
important for peanut in children with early onset severe eczema and/or egg allergy, as we have 197 
high-quality evidence with the LEAP study that early consumption of peanut is protective. The 198 
use of SPT and specific IgE testing should be based on a consciously defined pre-test 199 
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probability and interpreted with caution, based on existing studies on the predictive values of 200 
SPT and specific IgE in infants and young children as much as possible (Table 2). In children 201 
younger than 2 years of age, lower levels of IgE and smaller weals on SPT are more likely to 202 
be clinically relevant as reflected by the lower levels for 95% PPV cut-offs and the shift in the 203 
curves for the probability of clinical reactivity for a given IgE level compared to older children 204 
(36-38). As new modalities of testing are being developed like the basophil activation test, 205 
optimal cut-offs seem to be different in this age group and further research is needed (Santos 206 
AF, unpublished). Allergy testing prior to weaning should be done with the possibility of 207 
offering families supervised introduction of foods, in the office or the hospital setting, 208 
depending on the risk of reactivity. This is particularly important in this age group as 209 
immunological changes can happen quite rapidly in the first few months of life and the risk of 210 
food allergy can change from one assessment to the other. For this reason, ideally, there would 211 
be priority access for food challenges for infants as part of specialized Allergy services.  212 
 213 
Tertiary prevention  214 
In the cases where food allergy could not be prevented, it is important to minimise the impact 215 
of food allergy in the lives of children and their families, the risk of accidental allergic reactions 216 
and the progression and complications that could arise from food allergy and accompanying 217 
atopic comorbidities (39-41). Following an accurate and definitive diagnosis of food allergy, 218 
it is important to recommend appropriate allergen avoidance and emergency medication to treat 219 
allergic reactions in the context of accidental allergen exposure. Keeping good control of 220 
asthma (and also allergic rhinitis and eczema) is very important as more severe reactions can 221 
develop in food allergic children with uncontrolled asthma. Education of patients and family 222 
about the nature of food allergies, reading labels and good communication with school, peers 223 
and family is paramount. The support of a specialised dietitian is invaluable to advise on the 224 
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practical management of food allergy, appropriate replacement foods and adequate nutrient 225 
intake. Support from a clinical psychologist may also be beneficial in case of significant 226 
anxiety, depression or other mental health issues of child and/or family related with food 227 
allergies.  228 
A definitive treatment of food allergy is highly expected. Immunomodulatory treatments have 229 
been investigated to try to modify the course of the disease and shut down the aberrant IgE-230 
mediated immune response to foods. Allergen immunotherapy (AIT) has shown to increase the 231 
threshold of clinical reactivity while on treatment (desensitisation) with a  subset of patients 232 
sustaining this effect following discontinuation of treatment (sustained unresponsiveness) (42-233 
44). The foods that have been studied the most are peanut, egg and cow’s milk. As AIT involves 234 
the administration of allergen to allergic patients, it incurs on a significant risk of allergic 235 
reactions during up-dosing and also during the maintenance phase, usually in the presence of 236 
co-factors, such as exercise, infection, menstruation and sleep deprivation (45). Some patients 237 
do not tolerate the side-effects and end up abandoning the treatment. Epicutaneous have a better 238 
safety profile than sublingual oral immunotherapy but the dose of allergen  administered and 239 
the dose tolerated increase in reverse order. The administration of anti-IgE omalizumab 240 
concomitantly with AIT reduces the rate of adverse events and allows more rapid updosing. 241 
Active research on omalizumab (e.g. OUtMATCH, NCT03881696) and other anti-IgE 242 
molecules, dupilumab (anti-IL4R – e.g. NCT03793608, NCT03682770, NCT04148352) and 243 
etokimab (anti-IL33) (46) in food allergy is being pursued, at different stages of development. 244 
Long-lasting disease-modifying effect of immunomodulatory treatments are yet to be 245 
demonstrated.  246 
 247 
Conclusion:  248 
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Food allergy is a significant public health problem and its increase seems to be related to 249 
environmental factors related to the Western modern life-style. The main hypothesis to explain 250 
this increase in food allergy prevalence, severity and persistence are the timing, dosing and 251 
route of exposure to food allergens in infancy, microbial exposure in early life and levels of 252 
vitamin D and possibly other factors. High quality evidence is lacking for many possible 253 
interventions to modify the food allergy risk. The main recommendation currently to prevent 254 
food allergy is to introduce allergenic foods in the infant’s diet alongside with breastfeeding as 255 
exposure to food allergens via the oral route is necessary for the establishment of oral tolerance 256 
and can be protective. Future research needs to focus on the search not only for evidence of 257 
interventions for food allergy prevention but also for definitive treatments for food allergy.  258 
 259 
Key points: 260 
• Food allergy affects 8% of children and 11% of adults and its prevalence, severity and 261 
persistence has increased over time.  262 
• For primary prevention of food allergy, introduction of allergenic foods, namely cooked 263 
egg and peanut, during weaning alongside breastfeeding is the main recommendation.  264 
• Immunomodulatory treatments, such as allergen-specific immunotherapy and biologics, 265 
have been explored and further research into curative treatments for food allergy is needed.  266 
 267 
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Tables 279 









• No avoidance of allergenic foods during 
pregnancy or breastfeeding. 
• Avoidance of temporary administration of 
standard cow’s milk formula in the first days of 
life. 
• Introduction of cooked egg and peanut (the latter 
in populations with high prevalence of peanut 







Introduction of peanut during weaning: 
• for infants with severe eczema and/or egg allergy 
at 4-6 months with consideration given to prior 
SPT/specific IgE testing 
• for infants with mild/moderate eczema around 6 
months of age 
• for infants without eczema or food allergy, 







• Weaning between 4-6 months, starting with iron-
rich foods, while continuing breast-feeding. 
• Introduction of allergenic foods during weaning for 
all infants, including peanut butter, cooked egg, dairy, 
and wheat. 
• Hydrolyzed (partially or extensively) infant 







  287 
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Table 2. Positive predictive value (PPV) cut-offs for skin prick test (100% PPV) and specific 288 
IgE (95% PPV) to diagnose common food allergies in infants and young children (38). ND, 289 
not determined.  290 
 291 
Food SPT Specific IgE 
Cow’s milk 6 mm 5 KU/L 
Egg 4 mm 2 KU/L 





Figure Legends: 295 
 296 
Figure 1. Main hypotheses to explain the rise in food allergy in recent decades 297 
 298 
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Notes on references: 438 
Gupta 2018 439 
*Recent questionnaire-based study performed in the USA providing recent data for 440 
prevalence and severity of food allergy in children. 441 
 442 
Gupta 2019 443 
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*Recent questionnaire-based study performed in the USA providing recent data for 444 
prevalence of food allergy in adults.  445 
 446 
Grimshaw 2020 447 
*Data from Europrevall birth cohort studies establishing moderate-severe eczema as 448 
a major risk factor for food allergy. 449 
 450 
Marrs 2019 451 
*Data from the EAT study in the UK demonstrating that dog ownership is a protective 452 
factor for the development of food allergy.  453 
 454 
B 2019 455 
*Excellent recent review on the evidence for the role of the microbiome in food 456 
allergy.  457 
 458 
Feehley 2019 459 
**Study in mouse models colonised with microbiome from healthy infants and infants 460 
with cow's milk allergy related specific bacteria in the ileum with protective and 461 
regulatory effects.  462 
 463 
Abdel-Gadir 2019 464 
*Study using mouse models identified a population of regulatory T cells induced as a 465 
result of bacteriotherapy to reverse dysbiosis and suppress food allergy.   466 
 467 
Silva 2020 468 
**Systematic review of randomized controlled trials of interventions aiming to 469 
prevent the development of food allergy, which formed the basis to the soon-to-be-470 
published EAACI Guidelines for food allergy prevention.  471 
 472 
U 2019 473 
**Randomized controlled trial demonstrating that supplementation with cow's milk 474 
formula in the first few days of life increases the risk of cow's milk allergy.  475 
 476 
Roberts 2019 477 
**Meta-analyses of studies of early introduction of allergenic foods demonstrates the 478 
benefits of eary introducton of egg and peanut (but not milk) in the prevention of food 479 
allergy.  480 
 481 
Pajno 2018 482 
**EAACI Guidelines on allergen-specific immunotherapy for food allergy 483 
recommending oral immunotherapy for peanut, egg and cow’s milk for children older 484 
than 4 years of age with persistent allergies to induce dessensitization, which should 485 
be undertaken only in specialized centres with the appropriate resources to treat 486 
anaphylaxis and ensure patient safety during treatment.  487 
 488 
Chu 2019 489 
**Systematic review and meta-analyses showing that patients submitted to oral 490 
peanut immunotherapy suffer more allergic reactions and anaphylaxis that those 491 
treated with placebo. 492 
 493 
